Industry News

Boston Herald The Ticker column [Boston Herald]
GUERBET : 2016 half-year results
EndoChoice, which markets a variety of gastrointestinal endoscopy products, headed by the Full Spectrum Endoscope, a unique Israeli-developed colonscope, today announced that it would be acquired by Boston Scientific for $210 million. EndoChoice is listed on Nasdaq at a $109 million market cap, meaning that the acquisition is at a premium of almost 100%. EndoChoice held its IPO in 2015, raising $96 million at a company value of $366 million, after money, and reached a peak..."/>
Boston Scientific buys EndoChoice for $210m [Globes, Tel Aviv, Israel]
Sanomedics, by lying that former Apple and Pepsi CEO John Sculley, Miami-based IVAX Corp. Chairman Phillip Frost and "Dog Whisperer" Cesar Millan were big investors or representatives,..."/>
FBI busts Miami Lakes boiler room operators in alleged $23 million scam [The Miami Herald]
Boston Scientific Corp. on Tuesday announced plans for a $210 million acquisition that would broaden the medical technology company's line of products for diagnosis and treatment of gastrointestinal conditions like colon cancer. Massachusetts-based Boston Scientific, which derives two-thirds of its revenue from divisions based in Minnesota, said it will acquire all the stock of EndoChoice Holdings in Alpharetta, Ga. The deal is expected to close by the end of the..."/>
Boston Scientific will pay $210M for endoscopy maker EndoChoice [Star Tribune (Minneapolis)]
Stereotaxis said Tuesday that it had made strategic changes that include securing a large equity investment and making key board appointments. The moves "should provide us with the opportunity to achieve profitability," Stereotaxis CEO William C. Mills said in a statement. Louis-based company that makes computerized systems to treat heart arrhythmias said it secured a $24 million equity investment from..."/>
Stereotaxis announces new investors, board members [St. Louis Post-Dispatch]
Allied Healthcare Products is proposing a reverse stock split to push its share price above $1.. Shares in Allied, a St. Louis manufacturer of respiratory products, have traded below $1 since January."/>
Allied Healthcare proposes reverse split to stay on Nasdaq [St. Louis Post-Dispatch]
Array BioPharma Inc. announced today the pricing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $6.25 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and offering expenses, are expected to be approximately $115 million. The offering is expected to close on or about October 3, 2016, subject to customary closing conditions."/>
Array BioPharma Announces Pricing of Public Offering of Common Stock
Allergan, a $4 billion-a-year maker of skin and eye care products. The company's treatment uses a virus to deliver a photoreceptor gene from the algae into a human..."/>
WSU research leads to algae treatment for blindness [Detroit Free Press]
MYnd Analytics, Inc. announces the publication of“ Using Electroencephalography for Treatment Guidance in Major Depressive Disorder” in the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. The study is a review of the current literature on biomarkers derived from electroencephalography and their role in guiding clinical treatment of major depression. The publication highlights the opportunity for machine..."/>
EEG is the Wave of the Future: Machine Learning Technology Highlighted in Biological Psychiatry Publication
McKesson Corp., is laying off 132 employees at its Cary facility. Biologics notified the state Department of Commerce last week that the layoffs will begin Nov. 21. The employees being laid off include 72 patient benefits specialists, 15 patient care coordinators and a dozen customer service representatives."/>
BRIEF: Cary's Biologics is laying off 132 employees [The News & Observer (Raleigh, N.C.)]
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, the underwriters have a 30- day option to purchase up to an additional 570,000..."/>
MyoKardia Announces Pricing of Proposed Public Offering of Common Stock
Xencor has expanded its San Diego operations, the Monrovia-based biotech said last week. The San Diego office now has 17 employees, said president and CEO Bassil Dahiyat. It had about four when it was opened about two years ago, They're handling clinical development and regulatory affairs."/>
Xencor grows in San Diego [The San Diego Union-Tribune]
Cantel Medical Corp has acquired endoscope reprocessing business assets from its Canadian medical products distributor, Vantage Endoscopy, Inc, the company said. Terms of the deal were not disclosed. The endoscope reprocessing business consists of Cantel's Medivators-branded automated endoscope reprocessors, chemistries, consumables and a full sales and service organization."/>
Cantel Medical Acquires Endoscopy Assets from Vantage Endoscopy
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, President and Chief Executive Officer, David Riggs, Chief Financial Officer, and other members of Eagle's senior management team will host an Investor Day in New York City on November 11, 2016.. The event will focus on the Company's growth initiatives, R&D pipeline and financial outlook. It will provide additional insight on Ryanodex ® for Exertional Heat Stroke and Methamphetamine and..."/>
Eagle Pharmaceuticals Announces “Save the Date” for 2016 Investor Day
Array BioPharma today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30- day option to purchase up to an additional $15 million of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma."/>
Array BioPharma Announces Proposed Public Offering of Common Stock
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dawn Svoronos has been appointed to its Board of Directors. Svoronos is a pharmaceutical industry executive whose experience includes a 23- year career at Merck& Co. with a focus on commercial operations and marketing, as well as board positions at Medivation Inc. and Theratechnologies Inc.. Simon Pimstone, Xenon’ s President and Chief..."/>
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology532 Articles
Consumer Discretionary470 Articles
Financials300 Articles
Industrials291 Articles
Health Care259 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.